Pfizer Ventures led the immuno-oncology drug developer's latest round, which was spun out of Institut Paoli-Calmettes with the help of Satt Sud-Est and Inserm Transfert.

ImCheck Therapeutics, a France-based cancer therapy spinout of Institut Paoli-Calmettes, completed a $53m series B round yesterday that was co-led by pharmaceutical firm Pfizer through its corporate venturing unit, Pfizer Ventures.
Boehringer Ingelheim Venture Fund, the investment arm of pharmaceutical company Boehringer Ingelheim, also participated in the round, as did Alexandria Venture Investments, life sciences real estate investment trust Alexandria Real Estate Equities’ venture capital vehicle.
Bpifrance’s InnoBio 2 and Large Venture funds co-led the round with Pfizer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?